从2017年美国临床肿瘤学会大会报告看早期乳腺癌治疗加减法
Treatment of early breast cancer: more or less? Study from the 2017 American Society of Clinical Oncology Annual Meeting

DOI: 10.6040/j.issn.1671-7554.0.2017.897

Keywords: 美国临床肿瘤学会,化疗,靶向治疗,早期乳腺癌,治疗进展,内分泌治疗,
American Society of Clinical Oncology,Chemotherapy,Targeted therapy,Treatment progress,Early breast cancer,Endocrine therapy

Full-Text   Cite this paper   Add to My Lib

Abstract:

References

[1]	Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer[J]. N Engl J Med, 2002, 347(16): 1233-1241.
[2]	Harbeck N, Gluz O, Clemens M, et al. Prospective WSG phase III Plan B trial: final analysis on adjuvant 4EC→4Doc vs. 6Docetaxel/Cyclophosphamidein high clinical and intermediate/high genomic risk HER2-negative early breast cancer[EB/OL].(2017-08-20).[2017-09-19]. http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.504.
[3]	Blum JL, Flynn PJ, Yothers G, et al. Anthracyclines in early breast cancer: the ABC trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49(NRG Oncology)[J]. J Clin Oncol, 2017, 35(23): 2647-2655.
[4]	Morrow M, Abrahamse P, Hofer TP, et al. Trends in reoperation after initial lumpectomy for breast cancer addressing overtreatment in surgical management[J]. JAMA Oncol, Published online, June 5, 2017. doi:10.1001/jamaoncol.2017.0774.
[5]	Gluz O, Nitz UA, Christgen M, et al. West German study group phase III PlanB trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment[J]. J Clin Oncol, 2016, 34(20): 2341-2349.
[6]	Colleoni M, Luo W, Karlsson P, et al. A phase 3 randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer[EB/OL].(2017-08-20).[2017-09-19]. http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.503.
[7]	Sabnis GJ, Macedo LF, Goloubeva O, et al. Stopping treatment can reverse acquired resistance to letrozole[J]. Cancer Res, 2008, 68(12): 4518-4524.
[8]	de Azambuja E, Holmes AP, Piccart-Gebhart M, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer(NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response[J]. Lancet Oncol, 2014, 15(10): 1137-1146.
[9]	Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant(HERA)trial[J]. Lancet, 2017, 389(10075): 1195-1205.
[10]	Moreno-Aspitia A, Holmes E, Jackisch C, et al. Updated results from the phase III ALTTO trial(BIG 2-06; NCCTG/Alliance N063D)comparing one year of anti-HER2 therapy with lapatinib alone(L), trastuzumab alone(T), their sequence(T→L)or their combination(L+T)in the adjuvant treatment of HER2-positive early breast cancer[EB/OL].(2017-08-20).[2017-09-19]. http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.502.
[11]	Pivot X, Romieu G, Debled M, et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer(PHARE): a randomized phase 3 trial[J]. Lancet Oncol, 2013, 14(8): 741-748.
[12]	National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. breast cancer, version 3.2017[EB/OL].[2017-11-10]. http//www.nccn.org/professionals/physician.gls/pdf/breast.pdf.
[13]	Nanda R, Liu MC, Yee D, et al. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer: result from the I-SPY 2 trial[EB/OL].(2017-08-20).[2017-09-19]. http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.508.
[14]	Joensuu H, Bono P, Kataja V, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial[J]. J Clin Oncol, 2009, 27(34): 5685-5692.
[15]	Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial[J]. Lancet Oncol, 2010,11(10): 927-933.
[16]	刘淼,王殊,彭媛,等. ACOSOG Z0011试验标准用于中国前哨淋巴结阳性乳腺癌患者以避免腋窝淋巴结清扫的可行性研究[J]. 中国癌症杂志,2015,25(2): 135-140. LIU Miao, WANG Shu, PENG Yuan, et al. The exportability of the criteria defined by Z0011 trial for selecting patients who are eligible for omitting ALND after a positive SLNB result in China[J]. China Oncology, 2015, 25(2): 135-140.
[17]	van Ramshorst MS, van Werkhoven E, Honkoop AH, et al. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: the TRAIN-2 study[J]. Breast, 2016, 29: 153-159. doi: 10.1016/j.breast.2016.07.017.
[18]	Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial[J]. Lancet, 2013, 381(9869): 805-816.
[19]	Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years[J]. N Engl J Med, 2016, 375(3): 209-219.
[20]	Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer(NeoSphere): a multicentre, open-label, phase 2 randomised trial[J]. Lancet Oncol, 2016, 17(6): 791-800.
[21]	von Minckwitz G, Procter M, de Azambuja E, et al. A randomized comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with HER2-positive early breast cancer[EB/OL].(2017-08-20).[2017-09-19]. http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.18_suppl.LBA500.
[22]	von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant Pertuzumab and Trastuzumab in early HER2-positive breast cancer[J]. N Engl J Med, 2017, 377(2): 122-131.
[23]	Conte PF, Bisagni G, Frassoldati A, et al. 9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: results of the phase III multicentric Italian Short-HER study[EB/OL].(2017-08-20).[2017-09-19].http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.501.
[24]	Bartsch R, de Azambuja E. I-SPY 2: optimising cancer drug development in the 21st century[J]. ESMO Open, 2016, 1(5): e000113. doi:10.1136/esmoopen-2016-000113.
[25]	Severson TM, Wolf DM, Yau C, et al. The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting[J]. Breast Cancer Res, 2017, 19(1): 99. doi: 10.1186/s13058-017-0861-2.
[26]	Echavarria I, López-Tarruella S, Márquez-Rodas I. Neratinib for the treatment of HER2-positive early stage breast cancer[J]. Expert Rev Anticancer Ther, 2017, 17(8): 669-679.

Full-Text